2023年重症监护药物治疗学文献重要出版物
本文旨在总结2023年描述危重症患者药物治疗的最重要和最具影响力的出版物。通过系统检索PubMed/MEDLINE和临床药学与药理学药物治疗文献更新,纳入2023年1月1日至12月31日发表的成人危重症患者随机对照试验和前瞻性研究,评估药物治疗干预并报告临床终点。系统检索和文献更新共返回1202篇文章,排除1164篇,剩余38篇经过三轮改良德尔菲流程,根据对科学知识的总体贡献和对文献的新颖性进行独立评分。纳入的文章主题包括氢化可的松治疗重症社区获得性肺炎、吸入阿米卡星预防呼吸机相关性肺炎、亚甲蓝治疗脓毒性休克、限制性与 liberal 液体管理治疗脓毒症诱导的低血压、andexanet alfa 治疗因子Xa抑制剂相关大出血、以及早期给予四因子凝血酶原复合物浓缩物用于有大量输血风险的创伤患者。
要点
- 系统检索返回1202篇文章,排除1164篇,剩余38篇进入三轮改良德尔菲流程。
- 纳入标准为2023年1月1日至12月31日发表的成人危重症患者随机对照试验和前瞻性研究,评估药物治疗干预并报告临床终点。
- 纳入文章主题包括氢化可的松治疗重症社区获得性肺炎、吸入阿米卡星预防呼吸机相关性肺炎、亚甲蓝治疗脓毒性休克。
- 还包括限制性与 liberal 液体管理治疗脓毒症诱导的低血压、andexanet alfa 治疗因子Xa抑制剂相关大出血、早期四因子凝血酶原复合物浓缩物用于有大量输血风险的创伤患者。
适用人群与场景
- 成人危重症患者,纳入随机对照试验和前瞻性研究,评估药物治疗干预并报告临床终点,发表于2023年1月1日至12月31日。
研究设计与关键结果
- 系统检索和临床药学与药理学药物治疗文献更新共返回1202篇文章,其中1164篇被排除,剩余38篇经过三轮改良德尔菲流程。
- 纳入文章主题包括氢化可的松治疗重症社区获得性肺炎、吸入阿米卡星预防呼吸机相关性肺炎、亚甲蓝治疗脓毒性休克、限制性与 liberal 液体管理治疗脓毒症诱导的低血压、andexanet alfa 治疗因子Xa抑制剂相关大出血、早期给予四因子凝血酶原复合物浓缩物用于有大量输血风险的创伤患者。
证据类型、等级与局限
- 证据类型:综述,采用系统检索和三轮改良德尔菲流程筛选文献。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: We aimed to summarize the most significant and impactful publications describing the pharmacotherapeutic care of critically ill patients in 2023.
DATA SOURCES: PubMed/MEDLINE and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update.
STUDY SELECTION: Randomized controlled trials and prospective studies of adult critically ill patients assessing a pharmacotherapeutic intervention and reporting clinical endpoints published between January 1, 2023, and December 31, 2023, were eligible for inclusion in this article.
DATA EXTRACTION: Articles from a systematic search and the Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update were included. An a priori defined three-round modified Delphi process was employed to achieve consensus on the most impactful publications based on the following considerations: 1) overall contribution to scientific knowledge and 2) novelty to the literature.
DATA SYNTHESIS: The systematic search and Clinical Pharmacy and Pharmacology Pharmacotherapy Literature Update returned a total of 1202 articles, of which 1164 were excluded. The remaining 38 articles underwent a three-round modified Delphi process. In each round, articles were independently scored based on overall contribution to scientific knowledge and novelty to the literature. Included articles are summarized and their impact discussed. Article topics included hydrocortisone for severe community-acquired pneumonia, inhaled amikacin for prevention of ventilator-associated pneumonia, methylene blue for septic shock, restrictive vs. liberal fluid management for sepsis-induced hypotension, andexanet alfa for major bleeding associated with factor Xa inhibitors, and early administration of four-factor prothrombin complex concentrate in patients with trauma at risk for massive transfusion.
CONCLUSIONS: This review provides a summary and perspective on the potential impact of the most relevant articles in 2023 describing advances in the pharmacotherapeutic care of critically ill patients.
参考来源
- Murray B, Athale J, Balk RA, et al. Major Publications in the Critical Care Pharmacotherapy Literature: 2023. Crit Care Explor. 2024. PMID: 39360775. doi:10.1097/CCE.0000000000001162
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。